by Paul | 30th January 2026 | News
London and New York, NY, January 30, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that...
by Paul | 28th January 2026 | News
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size, and development approach London and New York, NY, January 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies...
by Paul | 23rd January 2026 | News
London and New York, NY, January 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that...
by Paul | 5th January 2026 | News
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board London and New York, NY, January 5, 2026. OKYO Pharma...
by Paul | 19th December 2025 | News
London and New York, NY, December 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related...
by Paul | 15th December 2025 | News
London and New York, NY, December 15, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe...
